The Coriell Personalized Medicine Collaborative is embarking on a new alliance with the U.S. Air Force.
Learn More ›
Coriell Institute has partnered with IBM to create a spin-off company: Coriell Life Sciences.
Learn More ›
Coriell offers a range of flexible, innovative, and
results-oriented research services that support national and international science. Learn More ›
Genetic variations influence why some people have a greater risk for cancer, or respond poorly to a particular medication. Learn More ›
Lewis L. Coriell, MD, PhD, founded the Institute with a vision of research translating into improved patient care. Learn More ›
Welcome to the Coriell Institute for Medical Research
Coriell Institute for Medical Research, founded in 1953 and based in Camden, New Jersey, is an independent non-profit research center dedicated to the study of the human genome. Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking drive our mission.
The emerging field of personalized medicine draws upon a person’s genomic information to tailor treatments and prescription drug dosing to optimize health outcomes. The Coriell Personalized Medicine Collaborative® (CPMC®) research study is seeking to understand the usefulness of genetic risk and pharmacogenomics in clinical decision-making and healthcare management.
Coriell has a distinguished history in cell biology. We are building upon this expertise by playing an important role in induced pluripotent stem (iPS) cell research. Induced pluripotent stem cells are powerful cells which can be made from skin or blood cells, and they are revolutionizing the way human disease is studied and how drugs are developed. Skin cells from a patient diagnosed with heart disease are being genetically reprogrammed into stem cells, and then transformed into beating cardiac cells. Researchers can now examine the heart-diseased cells to better understand the progression of heart disease and develop treatments and cures. Drug efficacy and safety can also be tested in this laboratory environment, providing an efficient model of drug discovery that delivers drugs to patients sooner. This technology, called "disease in a dish," offers researchers the potential to study the myriad of human diseases, including Alzheimer's disease, muscular dystrophy, and diabetes.
In addition to pioneering cutting-edge research initiatives, Coriell offers custom research services – including cell culture, cytogenetic analyses, and molecular biology – to the scientific community. Furthermore, Coriell’s Genotyping and Microarray Center is one of the nation’s largest centers, with high-throughput DNA analysis, CLIA-certified genotyping platforms systems from Illumina and Affymetrix.
Essential to the Institute’s support of international scientific research is the Coriell Biobank. From this renowned cell bank, we manage and distribute the world’s most diverse collection of cell lines, DNA, and other biological resources. The Coriell Biobank provided support to the Human Genome Project, a worldwide program to map the entire human genome, and to the International HapMap Project, a project providing an efficient tool to identify disease-causing genes.
Coriell’s biobanking operation is funded by several National Institutes of Health awards. Our independent research programs rely on private philanthropy from donors like you.
Welcome to Coriell. Come and explore research with us.
In The Spotlight
Coriell In The News
Coriell Awarded $10M for Induced Pluripotent Stem Cell Program
May 2013 An exciting new stem cell initiative has engaged Coriell Institute. Read more ›
Coriell, IBM Form Spin-off Company
April 2013 Coriell Institute partners with IBM to form a spin-off venture, Coriell Life Sciences. Read more ›
Coriell Life Sciences
Giving to Coriell
As a non-profit institute, Coriell is fortunate to be engaged in several federally-funded awards. However, we rely on private philanthropy for our more cutting-edge, independent research. Thank you for supporting science!